MMED vs PODD
MMED: MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management. PODD: Insulet Corporation provides tubeless, wearable insulin management technology that simplifies diabetes care for millions of patients worldwide.
Side-by-side fundamentals
| Metric | MMED | PODD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.33 | $158.93 | |
| Market cap as of 2026-07-23 | $4.6B | $11.3B | |
| P/E as of 2026-07-23 | n/a | 37.44 | |
| PEG as of 2026-07-23 | n/a | 1.23 | |
| Net margin as of 2026-07-23 | -10.7% | +10.4% | PODD higher |
| Gross margin as of 2026-07-23 | +54.2% | +71.0% | PODD higher |
| Operating margin as of 2026-07-23 | -6.1% | +14.6% | PODD higher |
| ROE as of 2026-07-23 | -9.2% | +17.4% | PODD higher |
| ROA as of 2026-07-23 | -7.2% | +7.5% | PODD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.63 | MMED lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +31.9% | |
| Revenue CAGR (3y) SEC XBRL | +12.1% | +27.5% | PODD higher |
| Beta as of 2026-07-23 | -0.10 | 1.10 | |
| 1-year return as of 2026-07-22 close | -11.7% | -44.3% | MMED higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.